On February 16, 2023 ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, reported Dr. Karim Chamie, Associate Professor of Urology at UCLA, will be presenting "Quality of life in QUILT 3.032 study: Patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) receiving IL-15R⍺Fc superagonist N-803 plus BCG" at the ASCO (Free ASCO Whitepaper) Genitourinary Cancers Symposium (ASCO GU) conference in San Francisco, February 16-18 (Press release, ImmunityBio, FEB 16, 2023, View Source [SID1234627305]). The Food and Drug Administration (FDA) is currently reviewing the Biologics License Application (BLA) for ImmunityBio’s N-803 plus BCG for the treatment of NMIBC CIS with a Prescription Drug User Fee Act (PDUFA) date of May 23, 2023.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details about the presentation are below:

Date: February 16, 2023
Track: Urothelial Carcinoma, Prostate Cancer-Advanced
Sub-Track: Symptoms, Toxicities, Patient-Reported Outcomes and Whole-Person Care
Title: Quality of life in QUILT 3.032 study: Patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) receiving IL-15R⍺Fc superagonist N-803 plus BCG
Presenter: Dr. Karim Chamie, Associate Professor of Urology at UCLA
Session: Poster Session B: Prostate Cancer and Urothelial Carcinoma
Abstract #: 495
Location: Poster Board J17
Session Times: 11:30 a.m.-1:00 p.m.; 5:45-6:45 p.m. PST

Participants are also invited to attend ImmunityBio’s Medical Affairs booth (#65). For full session details and scientific presentation listings, please see the ASCO (Free ASCO Whitepaper) GU online program.